2022
Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases
Hausmann J, Program in Rheumatology, Kennedy K, Surangiwala S, Larche M, Sinha R, Durrant K, Foster G, Levine M, Thabane L, Costello W, Robinson P, Liew J, Yazdany J, Sirotich E, Division of Rheumatology and Clinical Immunology B, Department of Health Research Methods E, Queen’s University School of Medicine K, Divisions of Rheumatology/Clinical Immunology and Allergy D, Systemic JIA Foundation C, Autoinflammatory Alliance S, Irish Children’s Arthritis Network T, School of Clinical Medicine F, Section of Rheumatology D, Division of Rheumatology D, Canadian Arthritis Patient Alliance T. Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. European Journal Of Rheumatology 2022, 9: 185-190. PMID: 35156622, DOI: 10.5152/eujrheum.2022.21133.Peer-Reviewed Original Research
2021
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritisAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Pons-Estel G, Isnardi C, Berbotto G, Hsu T, D’Silva K, Patel N, Kearsley-Fleet L, Schäfer M, Ribeiro S, Al Emadi S, Tidblad L, Scirè C, Raffeiner B, Thomas T, Flipo R, Avouac J, Seror R, Bernardes M, Cunha M, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, de Souza V, da Mota L, Gomides A, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J, Dahou B, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de Fernandez S, Argentina C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta-Montiel B, Castillo-Ortiz A, Zamora-Tehozol E, Vega-Morales D, Rosete D, Martín-Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals Of The Rheumatic Diseases 2021, 80: 1137-1146. PMID: 34049860, PMCID: PMC8172266, DOI: 10.1136/annrheumdis-2021-220418.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsCOVID-19 severitySynthetic disease-modifying antirheumatic drugsWorse COVID-19 severityRheumatoid arthritisBaseline useCOVID-19 severity outcomeTumor necrosis factor inhibitorsInterleukin-6 inhibitorsNecrosis factor inhibitorsPotential baseline confoundersCOVID-19 outcomesPhysician registryCOVID-19IL-6iAntirheumatic drugsClinical onsetBaseline confoundersFactor inhibitorsOrdinal logistic regressionDrug classesRituximabAbataceptTNFiHospitalisation
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds